Skip to main content
ASHI 51st Annual Meeting Main banner

E. Steve Woodle, MD

Professor of Surgery with Tenure, Co Director, Center for Transplant Immunology, Cincinnati Children's Hospital Medical Center
University of Cincinnati, Cincinnati Children's Hospital Medical Center
Liberty Township, OH

Dr. Woodle graduated from Texas A and M University and the University of Texas Medical Branch. He completed general surgery and research training at University of California, Davis, and multiorgan transplant and transplant immunology training at the University of Chicago.

Dr. Woodle currently is a tenured Professor of Surgery and the William A. Altemeier Endowed Chair in Surgery. He also co-directs the Center for Transplant Immunology at Cincinnati Children's.

His research has produced over 1000 scientific papers/abstracts with over 20,000 citations. Dr. Woodle conceptualized genetic engineering of OKT3 that produced a CDR grafted, Fc receptor mutated version now known as teplizumab (TShield). He showed that teplizumab was devoid of cytokine release and retained rejection efficacy. In 2023, teplizumab (Tzield®) became the first FDA approved drug to immunomodulate type 1 diabetes.

Dr. Woodle's early research focused on tacrolimus-based rejection therapy. He described the mixed acute rejection clinical phenotype that constitutes almost half of kidney transplant rejection episodes. In antibody mediated rejection, he developed plasma cell targeted therapies using proteasome inhibitors (bortezomib and carfilzomib). More recently he has combined plerixafor-based bone marrow niche targeted therapy with bortezomib. Dr. Woodle and colleagues are currently defining human rejection using single cell genomics/multiomics technologies.

Presentation(s):